98
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Modulation of HJURP (Holliday Junction-Recognizing Protein) Levels Is Correlated with Glioblastoma Cells Survival

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background

          Diffuse astrocytomas are the most common type of primary brain cancer in adults. They present a wide variation in differentiation and aggressiveness, being classified into three grades: low-grade diffuse astrocytoma (grade II), anaplastic astrocytoma (grade III) and glioblastoma multiforme (grade IV), the most frequent and the major lethal type. Recent studies have highlighted the molecular heterogeneity of astrocytomas and demonstrated that large-scale analysis of gene expression could help in their classification and treatment. In this context, we previously demonstrated that HJURP, a novel protein involved in the repair of DNA double-strand breaks, is highly overexpressed in glioblastoma.

          Methodology/Principal Findings

          Here we show that HJURP is remarkably overexpressed in a cohort composed of 40 patients with different grade astrocytomas. We also observed that tumors presenting the higher expression levels of HJURP are associated with poor survival prognosis, indicating HJURP overexpression as an independent prognostic factor of death risk for astrocytoma patients. More importantly, we found that HJURP knockdown strongly affects the maintenance of glioblastoma cells in a selective manner. Glioblastoma cells showed remarkable cell cycle arrest and premature senescence that culminated in elevated levels of cell death, differently from non-tumoral cells that were minimally affected.

          Conclusions

          These data suggest that HJURP has an important role in the maintenance of extremely proliferative cells of high-grade gliomas and point to HJURP as a potential therapeutic target for the development of novel treatments for glioma patients.

          Related collections

          Most cited references20

          • Record: found
          • Abstract: found
          • Article: not found

          Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis.

          Previously undescribed prognostic subclasses of high-grade astrocytoma are identified and discovered to resemble stages in neurogenesis. One tumor class displaying neuronal lineage markers shows longer survival, while two tumor classes enriched for neural stem cell markers display equally short survival. Poor prognosis subclasses exhibit markers either of proliferation or of angiogenesis and mesenchyme. Upon recurrence, tumors frequently shift toward the mesenchymal subclass. Chromosomal locations of genes distinguishing tumor subclass parallel DNA copy number differences between subclasses. Functional relevance of tumor subtype molecular signatures is suggested by the ability of cell line signatures to predict neurosphere growth. A robust two-gene prognostic model utilizing PTEN and DLL3 expression suggests that Akt and Notch signaling are hallmarks of poor prognosis versus better prognosis gliomas, respectively.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Time-dependent ROC curves for censored survival data and a diagnostic marker.

            ROC curves are a popular method for displaying sensitivity and specificity of a continuous diagnostic marker, X, for a binary disease variable, D. However, many disease outcomes are time dependent, D(t), and ROC curves that vary as a function of time may be more appropriate. A common example of a time-dependent variable is vital status, where D(t) = 1 if a patient has died prior to time t and zero otherwise. We propose summarizing the discrimination potential of a marker X, measured at baseline (t = 0), by calculating ROC curves for cumulative disease or death incidence by time t, which we denote as ROC(t). A typical complexity with survival data is that observations may be censored. Two ROC curve estimators are proposed that can accommodate censored data. A simple estimator is based on using the Kaplan-Meier estimator for each possible subset X > c. However, this estimator does not guarantee the necessary condition that sensitivity and specificity are monotone in X. An alternative estimator that does guarantee monotonicity is based on a nearest neighbor estimator for the bivariate distribution function of (X, T), where T represents survival time (Akritas, M. J., 1994, Annals of Statistics 22, 1299-1327). We present an example where ROC(t) is used to compare a standard and a modified flow cytometry measurement for predicting survival after detection of breast cancer and an example where the ROC(t) curve displays the impact of modifying eligibility criteria for sample size and power in HIV prevention trials.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              COMPLEX LANDSCAPES OF SOMATIC REARRANGEMENT IN HUMAN BREAST CANCER GENOMES

              SUMMARY Multiple somatic rearrangements are often found in cancer genomes. However, the underlying processes of rearrangement and their contribution to cancer development are poorly characterised. Here, we employed a paired-end sequencing strategy to identify somatic rearrangements in breast cancer genomes. There are more rearrangements in some breast cancers than previously appreciated. Rearrangements are more frequent over gene footprints and most are intrachromosomal. Multiple architectures of rearrangement are present, but tandem duplications are common in some cancers, perhaps reflecting a specific defect in DNA maintenance. Short overlapping sequences at most rearrangement junctions suggest that these have been mediated by non-homologous end-joining DNA repair, although varying sequence patterns indicate that multiple processes of this type are operative. Several expressed in-frame fusion genes were identified but none were recurrent. The study provides a new perspective on cancer genomes, highlighting the diversity of somatic rearrangements and their potential contribution to cancer development.
                Bookmark

                Author and article information

                Contributors
                Role: Editor
                Journal
                PLoS One
                PLoS ONE
                plos
                plosone
                PLoS ONE
                Public Library of Science (San Francisco, USA )
                1932-6203
                2013
                25 April 2013
                : 8
                : 4
                : e62200
                Affiliations
                [1 ]Department of Clinical Analysis, Faculty of Pharmaceutical Sciences of Araraquara, University of São Paulo State (UNESP), Araraquara, Brazil
                [2 ]Center for Integrative Systems Biology (CISBi), NAP-USP, Ribeirão Preto, Brazil
                [3 ]Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos, Brazil
                [4 ]Department of Surgery and Anatomy, Faculty of Medicine of Ribeirão Preto, University of São Paulo (USP), Ribeirão Preto, Brazil
                [5 ]Department of Cellular and Molecular Biology, Faculty of Medicine of Ribeirão Preto, University of São Paulo (USP), Ribeirão Preto, Brazil
                [6 ]Department of Neurology, Faculty of Medicine, University of São Paulo (USP), São Paulo, Brazil
                NIH/NCI, United States of America
                Author notes

                Competing Interests: The authors Sueli Mieko Oba-Shinjo and Suely Kazue Nagahashi Marie are holders of patent rights related with the utilization of HJURP for diagnosis and treatment of astrocytomas. Patent information is described below: US Patent and Trademark Office US; Express mailing number: EV716301395US; Customer number: 23628; File reference: L0461.70171; Data of deposit: 25 april 2008; Earliest priority: 26 April 2007; Title of the invention: Methods for diagnosis and treating astrocytomas. European Patent Office; Application n° 08826602.8-2403 PCT/US2008005388; Date of filing: 25/04/2008; Priority US/26.04.07/USP 926263; Title: Methods for diagnosing and treating astrocytomas. This does not alter the authors’ adherence to all the PLOS ONE policies on sharing data and materials.

                Contributed with tissue samples handling: DPdCT. Reviewed manuscript: EME SMOS CGC. Conceived and designed the experiments: VV MLPL CGC. Performed the experiments: VV RBS LCdO FSA RT. Analyzed the data: VV MLPL. Contributed reagents/materials/analysis tools: DPdCT EME SMOS SKNM MLPL CGC. Wrote the paper: VV MLPL.

                Article
                PONE-D-12-01127
                10.1371/journal.pone.0062200
                3636219
                23638004
                34da2a80-c55c-4464-b06e-810037e56975
                Copyright @ 2013

                This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

                History
                : 11 January 2012
                : 20 March 2013
                Page count
                Pages: 10
                Funding
                The study was funded by the Brazilian governmental agencies Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP, #2004/12133-6), Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq, #485342/2006-5) and Fundação de Apoio ao Ensino, Pesquisa e Assistência (FAEPA) do Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto. This work has also been supported by fellowships from FAPESP (#2006/57602-9; #2011/05674-4), CNPq (#154707/2006-6; #19347/2011), and CAPES (Coordenação de Aperfeiçoamento de Pessoal de Nível Superior). EME, SMOS, SKNM, MLPL and CGC are CNPq fellows. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
                Categories
                Research Article
                Medicine
                Clinical Research Design
                Cohort Studies
                Diagnostic Medicine
                Pathology
                General Pathology
                Biomarkers
                Epidemiology
                Biomarker Epidemiology
                Oncology
                Cancers and Neoplasms
                Neurological Tumors
                Astrocytoma
                Glioblastoma Multiforme

                Uncategorized
                Uncategorized

                Comments

                Comment on this article